高级检索
当前位置: 首页 > 详情页

A seven-long noncoding RNA signature predicts overall survival for patients with early stage non-small cell lung cancer

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China [2]Department of Surgical Intensive Care Units, The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an 710061, Shaanxi, China [3]Institute of Clinical Medical Sciences, China‐Japan Friendship Hospital, Beijing 100029, China [4]Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China
出处:
ISSN:

关键词: long non-coding RNA NSCLC overall survival risk score stage I

摘要:
Non-small cell lung cancer (NSCLC) is the most common cancer and cause of cancer-related mortality globally. Increasing evidence suggested that the long non-coding RNAs (lncRNAs) were involved in cancer-related death. To explore the possible prognostic lncRNA biomarkers for NSCLC patients, in the present study, we conducted a comprehensive lncRNA profiling analysis based on 1902 patients from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) datasets. In the discovery phase, we employed 682 patients from the combination of four GEO datasets (GSE30219, GSE31546, GSE33745 and GSE50081) and conducted a seven-lncRNA formula to predict overall survival (OS). Next, we validated our risk-score formula in two independent datasets, TCGA (n=994) and GSE31210 (n=226). Stratified analysis revealed that the seven-lncRNA signature was significantly associated with OS in stage I patients from both discovery and validation groups (all P<0.001). Additionally, the prognostic value of the seven-lncRNA signature was also found to be favorable in patients carrying wild-type KRAS or EGFR. Bioinformatical analysis suggested that the seven-lncRNA signature affected patients' prognosis by influencing cell cycle-related pathways. In summary, our findings revealed a seven-lncRNA signature that predicted OS of NSCLC patients, especially in those with early tumor stage and carrying wild-type KRAS or EGFR.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 2 区 生物
小类 | 3 区 细胞生物学
最新[2025]版:
JCR分区:
出版当年[2016]版:
Q2 CELL BIOLOGY
最新[2023]版:
Q2 CELL BIOLOGY Q2 GERIATRICS & GERONTOLOGY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2016版] 出版当年五年平均[2012-2016] 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者单位: [1]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China [2]Department of Surgical Intensive Care Units, The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an 710061, Shaanxi, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)